Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — Investor Presentation (June 2019)
20 slides from Armata Pharmaceuticals's investor presentation, Jun 24, 2019
Slide 1: Armata Pharmaceuticals Investor Presentation
Todd Patrick, Chief Executive Officer Brian Varnum, President and Chief Development Officer Steve Martin, Chief Financial Officer As of June 24, 2019 NYSE American: ARMP
Slide 2: Forward-looking statements
2 I This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - looking statements . All
Slide 3: Investment Highlights: A World-Leader in Phage Therapeutics
3 I • Phage discovery and synthetic biology yield robust pipeline – Phase 1/2 ready S. aureus phage product candidate – P. aeruginosa phage product candidates • Pneumonia and cystic fibrosis phage product candidates identified • Synthetic phage with improved pharmacology engineered – Merck partnersh
Slide 4: Armata Stands on Long History of Phage Development
4 I Armata Stands on Long History of Phage Development M&A Yields Leading Phage Company Biocontrol Ltd. Pre - IND S. aureus and P. aeruginosa phage SGI Asset Acquisition Synthetic phage platform ▪ Pseudomonas program ▪ Pharma partnered program GMP Facility 25 MDR Cases Under EIND Targeted Antimicrob
Slide 5: Leadership and Board of Directors
5 I Leadership and Board of Directors Diverse Public Company Drug Development Expertise Management Todd R. Patrick CEO Steve Martin CFO Brian Varnum President and CDO Duane Morris VP, Operations Board of Directors Richard Bastiani Chair Joseph M. Patti Richard Bear Michael S. Perry Jeremy Curnock Co
Slide 6: Unmet Need in Antibiotic Resistant Infections
6 I Unmet Need in Antibiotic Resistant Infections Phages May Provide a Powerful Solution to an Urgent Public Health Threat
Slide 7: Bacteriophages Infection Yields Progeny and Results in Bacterial Lysis
7 I Bacteriophages Infection Yields Progeny and Results in Bacterial Lysis Source: Prescott Harley Klein’s Microbiology, 7th Ed. • The most ubiquitous organisms on Earth • Natural predators of bacteria • Highly targeted • Prior history as therapeutic agent – Antibiotics displaced phage use • Drug -
Slide 8: Deadly Infections Successfully Treated With Phage
8 I Deadly Infections Successfully Treated With Phage
Slide 9: Phage Therapy Now And In the Future
9 I Phage Therapy Now And In the Future Compelling Attributes of Phage • Life - changing outcomes in EIND cases – Sufficient proof to advance to formal clinical trials • Highly specific bactericidal agents – Minimal disruption of microbiome • Mechanism of action distinct from antibiotics • Replicati
Slide 10: Pipeline: Multiple Opportunities for Value Creation
10 I Pipeline Multiple Opportunities for Value Creation Pathogen Indications Discovery Preclinical Phase 1 Phase 2 Staphylococcus aureus Bacteremia Pseudomonas aeruginosa Respiratory Undisclosed Undisclosed Partnered AP - SA01 Phage libraries to address market expansion and new indications
Slide 11: AP-SA01 Phage Product Candidate Targeting S. aureus
11 I AP - SA01 Phage Product Candidate Targeting S. aureus Drug product 3 phages Covers >95% of S. aureus clinical isolates, including multidrug - resistant isolates Human dosing (US FDA: EIND; Aust TGA: SAS) 15 patients with serious infections not responding to antibiotics • Bacteremia, endocarditi
Slide 12: AP-SA01: Regulatory and Clinical Status
12 I Advanced Through Pre - IND Meeting • Highlighted prior human exposure under expanded access programs in U.S. and Australia • General agreement on proposed trial designs (Phase 1/2) • Nonclinical data not required; in line with FDA’s flexible approach to non - traditional antimicrobials Phase 1/
Slide 13: S. aureus Bacteremia
13 I S. aureus Bacteremia • 1.5 million Americans develop bacteremia each year resulting in ~250,000 deaths 1 • 1 in 3 patients who die in hospital have bacteremia 1 • The most costly condition treated at U.S. hospitals; ~$24 billion annually 2 • S. aureus is the second most common pathogen associat
Slide 14: Pseudomonas Phage Respiratory Development Strategy
14 I Pseudomonas Phage Respiratory Development Strategy Significant Medical Need and Synergy With Existing S. aureus Phage Product Pseudomonas aeruginosa • Covers ~20% of hospitalized pneumonia • Present in ~70% of chronic CF patients over age 25 – Major predictor of morbidity, mortality Staphylococ
Slide 15: Pseudomonas Phage Product Candidate
15 I Pseudomonas Phage Product Candidate Phage discovery effort provide basis for engineering Phage families with attractive attributes identified Cocktails developed for pneumonia and cystic fibrosis Engineer super fit phage Incorporating best attributes from a family Improved bactericidal and biof
Slide 16: Pseudomonas Phage Production and Formulation
16 I • Liquid formulation for first - in - human trial – Suitable for IV and inhalation • Successful manufacturing of first 2 Pseudomonas phage – GMP lots at intended Phase 1 scale Pseudomonas Phage Production and Formulation Utilizing Armata’s Proprietary Phage - Specific GMP Test Specification Pha
Slide 17: Strong Global IP Position Through Pending and Issued Patents
17 I Strong Global IP Position Through Pending and Issued Patents 12 Patent Families, Long - Life Patents, Patents Granted in all Major Jurisdictions Expiries through 2038 Armata’s patents and applications cover: Lead therapeutic phage cocktails (Staphylococcus and Pseudomonas) and uses thereof Comp
Slide 18: Anticipated Milestones 2019/2020
18 I AP - SA01 • Initiate Phase 1/2 clinical study in bacteremia Pseudomonas phage product candidate • Conduct Pre - IND meeting and file IND • Initiate first - in - human clinical study Anticipated Milestones 2019/2020
Slide 19: Investment Highlights: A World-Leader in Phage Therapeutics
19 I Investment Highlights A World - Leader in Phage Therapeutics Lead candidate, AP - SA01, positioned to enter clinical development Natural phage discovery and synthetic biology yield robust pipeline Merck partnership to develop proprietary synthetic phage to target an undisclosed infectious disea
Slide 20: Armata Pharmaceuticals
'~ ARMATA PHARMACEUTICALS PURPOSEFUL @ PRECISE ¢ POWERFUL
Armata Pharmaceuticals — Investor Presentation (June 2019) on 6ix